Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16705986 | 0.94 | CASP2 (0.57) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL23489532 | 0.89 | MEN1 (0.54) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL16123439 | 0.87 | MCL1 (0.47) | CASP2EPHX1MEN1KMT2AMMP2 | |
| SCHEMBL12314650 | 0.86 | CASP2 (0.47) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL9879638 | 0.84 | CES2 (0.55) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL22931570 | 0.81 | PAOX (0.53) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL12656851 | 0.81 | CASP2 (0.43) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL19069757 | 0.81 | CASP2 (0.50) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL16946573 | 0.80 | MEN1 (0.44) | CASP2MEN1KMT2ACNR1 | |
| SCHEMBL23475954 | 0.80 | MEN1 (0.39) | CASP2MEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | CASP2 1753/4885EPHX1 891/4885MEN1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.